Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms
Interventions: Embosphere microspheres; Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 50 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cardiomyopathy, Hypertrophic
Interventions: LCZ696, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Muscular Hypertrophy
Interventions: high protein milk, Placebo; Dietary Supplement
Lead sponsor: Marymount University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: HCC, Resection, Transplant, Metastatic Cancer, Adult Primary Liver Cancer
Interventions: Y90 radioembolization; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Jacksonville, Florida • Chicago, Illinois

Conditions: Muscle Composition, Sarcopenia, Hypertrophy, Inflammation
Interventions: Dietary Protein Intake; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 55 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Chronic Rhinitis, Inflammation of the Nasal Mucosa, Inflammation of Nasal Tissue
Interventions: Surgical turbinate reduction procedure; Procedure
Lead sponsor: ArthroCare Corporation; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: San Diego, California • Aurora, Colorado • Boynton Beach, Florida + 2 more

Conditions: Benign Prostatic Hyperplasia
Interventions: LY500307, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more

Conditions: Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
Interventions: Lovaza group; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation
Interventions: LARIAT LAA, WATCHMAN; Device
Lead sponsor: Kansas City Heart Rhythm Institute; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cardiomyopathy, Hypertrophic
Interventions: stop exercising; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fabry Disease
Interventions: Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more

Conditions: Muscle Hypotrophy
Interventions: Carnipure AAS, Creatine Monohydrate; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiomyopathy
Interventions: Not listed
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more

Conditions: Aging
Interventions: Protein, Placebo; Dietary Supplement · Other
Lead sponsor: Florida State University; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Breast Hypertrophy, Abdominal Elastosis, Breast Reconstruction
Interventions: wound closure device (Steri-Strip™); Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Muscle Hypertrophy, Muscle Strength
Interventions: Resistance training; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions: Survey using a questionnaire.; Other
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Evaluation of Patients With Known or Suspected Heart Disease

Resistance Training and Milk Supplementation

Optimizing Y90 Therapy for Radiation Lobectomy

Effects of Increased, Egg-Based Protein Intake on Muscle Composition,

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

A Study in Men With Benign Prostatic Hyperplasia

Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

Functional Capacity and Quality of Life Following Septal Myectomy in Patients With HCM

Safety and Efficacy of Left Atrial Appendage Occlusion Devices

Exercise Study Including Patients With Hypertrophic Cardiomyopathy

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Assessment of the Efficacy of Carnipure® AAS on Body Composition, Muscle Thickness, and Strength Adaptations in Healthy Men

UTSW HP [13-C] Pyruvate Injection in HCM

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training

Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Octreotide in Severe Polycystic Liver Disease

Hip Thrust Versus Back Squat Training in Untrained Adults

A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms